To help CDC increase understanding of the effectiveness of using maternal tenofovir containing combination drug during the second and third trimesters of pregnancy for the prevention of mother-to-child transmission of HIV and HBV in co-infected mothers.

To support state and local health departments in implementing Pregnancy Risk Assessment Monitoring System (PRAMS), streamlining data collection and providing actionable insights to inform public health strategies.